HELLO PHARMA: sector benchmark
Where does a company stand against its sector? Every ratio over five fiscal years, with its place among its peers and what that means, ready to print for your client.
HELLO PHARMA
Summary
HELLO PHARMA does better than half of its sector on 7 of the 8 ratios compared.
- Return on assetsbetter than 90%
- Return on equitybetter than 84%
- Interest coveragebetter than 75%
- Debt to equitybetter than 49%
Solvency and debt
Solvency is above 61% of 912 sector peers: more favourable than the median.
Position against the sector improving since 2021.
Debt to equity is above 51% of 902 sector peers: less favourable than the median.
Position against the sector stable since 2021.
The long-term debt ratio is below 61% of 339 sector peers: more favourable than the median.
Position against the sector stable since 2021.
Interest coverage is above 75% of 805 sector peers: in the most favourable quarter.
Position against the sector stable since 2021.
Liquidity
The current ratio is above 61% of 889 sector peers: more favourable than the median.
Position against the sector improving since 2021.
The working-capital ratio is above 60% of 911 sector peers: more favourable than the median.
Position against the sector improving since 2021.
Profitability
Return on equity is above 84% of 773 sector peers: in the most favourable quarter.
Position against the sector weakening since 2021.
Return on assets is above 90% of 910 sector peers: in the most favourable quarter.
Position against the sector weakening since 2021.
Not computable
Net margin, EBITDA margin, Gross margin, Days sales outstanding, Days payable outstanding, Days inventory. This company files the abbreviated or micro schema, in which turnover and purchases are optional; margins and credit terms therefore cannot be taken from its figures.
Source: filed annual accounts (NBB) and main activity (CBE register). Compared per fiscal year with each peer's latest statutory accounts; at least 30 peers per ratio. Prepared on 28 September 2026 via checked.be.